Cryo-Cell International, Inc.CCELNYSE
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-53.21%
↓ 122% below average
Average (39q)
239.52%
Historical baseline
Range
High:7635.84%
Low:-97.44%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -53.21% |
| Q2 2025 | 34.20% |
| Q1 2025 | -67.78% |
| Q4 2024 | 57.08% |
| Q3 2024 | -19.56% |
| Q2 2024 | -52.06% |
| Q1 2024 | 13.31% |
| Q4 2023 | 28.96% |
| Q3 2023 | 12.95% |
| Q2 2023 | 286.49% |
| Q1 2023 | 3.18% |
| Q4 2022 | -4.82% |
| Q3 2022 | -0.77% |
| Q2 2022 | -45.05% |
| Q1 2022 | 657.66% |
| Q4 2021 | 94.23% |
| Q3 2021 | 209.05% |
| Q2 2021 | -47.71% |
| Q1 2021 | -12.32% |
| Q4 2020 | 465.71% |
| Q3 2020 | -87.29% |
| Q2 2020 | 71.64% |
| Q1 2020 | -66.07% |
| Q4 2019 | 591.15% |
| Q3 2019 | -50.78% |
| Q2 2019 | -15.75% |
| Q1 2019 | -78.14% |
| Q4 2018 | 21.07% |
| Q3 2018 | -24.07% |
| Q2 2018 | 118.39% |
| Q1 2018 | -23.30% |
| Q4 2017 | 7635.84% |
| Q3 2017 | -97.44% |
| Q2 2017 | -39.52% |
| Q1 2017 | -21.61% |
| Q4 2016 | 35.30% |
| Q3 2016 | 14.95% |
| Q2 2016 | 38.05% |
| Q1 2016 | -34.75% |
| Q4 2015 | 33.73% |